Bambusa Therapeutics and Aspen Neuroscience Shares Decline Following Nasdaq IPO Debuts
Bambusa Therapeutics (BBTX) and Aspen Neuroscience (ASPE) experienced downward price movement on Friday following their initial public offerings on the Nasdaq. Bambusa, a Boston-based developer of bispecific antibody therapies, commenced trading at approximately $14.88 during the morning session. Aspen Neuroscience, which specializes in cell therapy treatments for Parkinson’s disease, also saw its shares trade lower upon listing. The simultaneous decline of both biotech IPOs reflects initial market volatility as these specialized healthcare companies begin public trading.
Topics: Biotechnology Nasdaq Listing Stock Market